IP Library Granted Patent US 8,829,043
Granted Patent B2
US 8,829,043 · App. 12/865,372 · Granted Sep 9, 2014

Oligome-cannabinoid conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,829,043
App. No.
12/865,372
Granted
Sep 9, 2014
Kind
B2
Abstract

The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.

Claims (17)

1. A compound having the following structure:

wherein:

X is a spacer moiety; and

POLY is a water-soluble, non-peptidic oligomer, wherein the water-soluble, non-peptidic oligomer is made of 2 to 30 monomers.

2. The compound of claim 1 , wherein the water-soluble, non-peptidic oligomer is a poly(alkylene oxide).

3. The compound of claim 2 , wherein the poly(alkylene oxide) is a poly(ethylene oxide).

4. The compound of claim 2 , wherein water-soluble, non-peptidic oligomer has between 2 and 20 monomers.

5. The compound of claim 4 , wherein the water-soluble, non-peptidic oligomer has between 2 and 10 monomers.

6. The compound of claim 2 , wherein the poly(alkylene oxide) includes an alkoxy or hydroxy end-capping moiety.

7. The compound of claim 1 , wherein X is selected from —O—, —S—, —NH—, —C(O)—NH—, —NH—C(O)—, —O—C(O)—NH—, —NH—C(O)—O—, NH—C(O)—NH, or a covalent bond.

8. The compound of claim 1 , wherein X is —O—.

9. A composition comprising a compound of claim 1 , and optionally, a pharmaceutically acceptable excipient.

10. A composition of matter comprising a compound of claim 1 , wherein the compound is present in a dosage form.

11. A compound having the structure:

wherein n is 1 to 30.

12. The compound of claim 11 , wherein n is 1 to 9.

13. A composition comprising a compound of claim 11 , and optionally, a pharmaceutically acceptable excipient.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 28571, FRAME 0141 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036866/0700 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
GRANT OF SECURITY INTEREST Recorded Jul 17, 2012
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 028571/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2012
From: RIGGS-SAUTHIER, JENNIFER; JUDE-FISHBURN, C. SIMONE; LALONDE, GUY
To: NEKTAR THERAPEUTICS
Reel/Frame 027651/0638 →